SEC EDGARJUN 121 min read$QURE

O'Keefe Kylie sold $431K of QURE

O'Keefe Kylie (Chief Customer & Strat Officer) sold 15,936 shares of uniQure N.V. (QURE) at $27.06 ($0.43M total) on 2026-06-11.

Original reporting

SEC EDGAR · O'Keefe Kylie

Published Jun 12, 2026, 9:55 PM UTC

Analysis

AlphAI AI DeskAI-generated

Added to AlphAI Jun 12, 2026, 9:57 PM UTC. Informational, not investment advice.

How this was made

AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.

About AlphAI AI Desk Scoring methodology Report an issue

AlphAI market briefInsider activity

Primary signal

$QURE

Bearish

medium confidence

Mentioned

$QURE

Relevance

4/10

AlphAI data visualization · based on SEC EDGAR

Decision brief

The 30-second read

$QUREBearishLow

Why it matters

The newest fact is the disclosed open-market sale by a named officer; absent any other corporate catalyst, it mainly affects short-term sentiment rather than valuation drivers.

Market read

Traders may monitor for follow-on insider activity, but this filing alone is unlikely to materially change the fundamental outlook.

What to watch

The article doesn’t provide context on total insider holdings, prior sales cadence, or whether other insiders/large holders are buying—so the signal may be noisy.

Relevance 4/10Novelty 6/10Timing: Filed 2026-06-12; sale executed 2026-06-11

Background

The article is an SEC Form 4 insider transaction disclosure for uniQure N.V. (QURE).

Company-level read

Ticker impact

AI estimates · verify against primary disclosures

$QUREBearishMedium confidence

Context

uniQure insider O'Keefe Kylie (Chief Customer & Strat Officer) sold 15,936 shares on 2026-06-11 at $27.0600 via open-market sale.

Expected impact

Near-term sentiment drag is possible, but magnitude is likely limited given it’s a single officer sale and no 10b5-1 plan is cited.

Evidence & confidence

The filing is primary-source (SEC Form 4) and the direction is sell, but the article provides no accompanying company-specific news (earnings, trial, guidance, deal, or enforcement) that would reset fundamentals.

Market effects

Sector

Minimal; this is company-specific insider activity with no sector-wide regulatory/clinical signal.

Regional

None indicated.

Global

None indicated.

Counterpoint

What could challenge this read

Insider sales can be driven by diversification, taxes, or pre-planned liquidity needs; without a 10b5-1 plan disclosed here, the sale still may not reflect a bearish view on the pipeline.

Key entities

issuer
uniQure N.V.
Subject of the Form 4 insider transaction disclosure.
insider
O'Keefe Kylie
Chief Customer & Strat Officer who sold 15,936 shares.
filing
SEC Form 4
Primary-source insider transaction report.

Read at source ← All news

OCT 8

$QUREHighAI 9/10

Is uniQure (QURE) Undervalued On New Huntingtons Data And FDA Filing Clarity?

uniQure (QURE) shares have fallen 48% in 30 days and 61.41% in 1 year, despite a 3x increase over 3 years. New Phase I/II data showed slowed Huntington's disease progression. Analysts debate if the stock is undervalued at $23.14, with fair value estimates ranging from $62.42 to $353.71, depending on future earnings and FDA approval.

simplywall.st2 min

OCT 7

$QUREHighAI 9/10

Gene Therapy Data Could Be A Big Moment For uniQure Stock (QURE)

uniQure (QURE) reported Phase I/II data for its Huntington’s disease gene therapy, showing slowed disease progression and a manageable safety profile. The FDA previously indicated that 36-month data could support an accelerated approval BLA. Analysts project significant revenue growth, with consensus estimates at $445.8M and earnings of $20.0M by 2029, though the company remains loss-making. The regulatory decision on the BLA is a key near-term focus for investors.

simplywall.st3 min

OCT 5

Med

UniQure Shares Fall After Barclays Downgrade

UniQure's shares declined after Barclays downgraded the company from Overweight to Equal Weight. The stock is currently trading at $22.81, down 2.77% on the day and 41.83% year-to-date. The downgrade is based on a weighted average of ratings including valuation, EPS revisions, and visibility.

marketscreener.com1 min

OCT 5

$QUREMed

QURE Downgraded by Barclays -- Price Target Lowered to $28.00

Barclays downgraded uniQure (QURE) from Overweight to Equal-Weight, lowering its price target from $60.00 to $28.00. The company's GF Value™ is $7.94, suggesting it's 195.5% overvalued. uniQure has a GF Score™ of 49/100, indicating mixed financial performance. Analysts cite concerns over financial health and market conditions.

gurufocus.com2 min

OCT 2

$QUREMedAI 8/10

RBC Capital cuts uniQure stock price target on trial data

RBC Capital reduced its price target for uniQure (QURE) to $48 from $65, citing trial data that missed statistical significance. The stock has fallen 39% in a week. Other analysts maintain bullish outlooks with higher targets. uniQure reported a wider-than-expected Q2 loss but revenue beat estimates. The company has FDA agreements for its Huntington’s disease gene therapy, AMT-130.

investing.com2 min

OCT 1

$QUREHighAI 8/10

uniQure (QURE) Reports New AMT 130 Data As FDA Opens Accelerated Review Path

uniQure (QURE) shared updated Phase I/II data for AMT-130, showing slowed Huntington’s disease progression. The FDA indicated 36-month high-dose data could support accelerated approval. The company focuses on gene therapies for rare conditions, with AMT-130 as a key catalyst.